Literature DB >> 19383521

Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape.

Tamaki Endoh1, Takashi Ohtsuki.   

Abstract

RNAi-mediated silencing of specific genes is a promising strategy for gene therapy. To utilize RNAi for therapy, an efficient and safe method for delivery of RNA into the cell cytosol is necessary. The plasma membrane is the primary, and most difficult, barrier for RNA to cross, because negatively charged RNA is strongly repulsed by the negatively charged membrane. A variety of cationic polymers can be used as RNA carriers by interacting with RNA and covering its negative charges to form a cell-penetrating complex. Among the emerging candidates for RNA carriers are cationic cell-penetrating peptides (CPPs), which can cross the plasma membrane and internalize into cells together with RNA. This review focuses on CPP-based RNA delivery strategies. In using CPP-based RNA delivery, most of the RNA internalized by the cell is entrapped in endosomes. Strategies for endosomal escape of RNAs are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383521     DOI: 10.1016/j.addr.2009.04.005

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  70 in total

1.  The optimization of polymalic acid peptide copolymers for endosomolytic drug delivery.

Authors:  Hui Ding; Jose Portilla-Arias; Rameshwar Patil; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Biomaterials       Date:  2011-04-22       Impact factor: 12.479

Review 2.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 3.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 4.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

Review 5.  Silk-based delivery systems of bioactive molecules.

Authors:  Keiji Numata; David L Kaplan
Journal:  Adv Drug Deliv Rev       Date:  2010-03-16       Impact factor: 15.470

6.  Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery.

Authors:  Haijun Yu; Yonglong Zou; Yiguang Wang; Xiaonan Huang; Gang Huang; Baran D Sumer; David A Boothman; Jinming Gao
Journal:  ACS Nano       Date:  2011-11-01       Impact factor: 15.881

7.  Novel protein transduction domain mimics as nonviral delivery vectors for siRNA targeting NOTCH1 in primary human T cells.

Authors:  A Özgül Tezgel; Gabriela Gonzalez-Perez; Janice C Telfer; Barbara A Osborne; Lisa M Minter; Gregory N Tew
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

8.  A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome.

Authors:  Kaleb M Pauley; Adrienne E Gauna; Irina I Grichtchenko; Edward K L Chan; Seunghee Cha
Journal:  Arthritis Rheum       Date:  2011-10

9.  Melittin derived peptides for nanoparticle based siRNA transfection.

Authors:  Kirk K Hou; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2013-02-04       Impact factor: 12.479

10.  Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo.

Authors:  Angela A Alexander-Bryant; Anca Dumitriu; Christopher C Attaway; Hong Yu; Andrew Jakymiw
Journal:  J Control Release       Date:  2015-09-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.